Skip to content
Est. 1998 proudly celebrating 27 years of standing behind American companies
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Nautilus Biotechnology, Inc. (NAUT)

$1.69 -4.52% NASDAQ: NAUT · 15-min delayed
  • SEATTLE, Washington
  • Public · NASDAQ: NAUT
  • 130 employees
$214.8MMarket cap
-$59.0MNet income
130Employees
NAUTNASDAQ
2021IPO

About Nautilus Biotechnology, Inc.

Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Its products includes: Proteome Analysis System, Reagent Kits, Software and analysis.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Net income
-$59.0M
Total assets
$191.1M
Market cap
$214.8M

Source: SEC EDGAR · updated Jun 7, 2026

Multi-year

Revenue & profit trend

Revenue Net income
FY 2025

Financial statements

Income statement

Operating expenses
$66.8M
Income tax
$0
Net income
-$59.0M
EPS (basic)
$-0.47
EPS (diluted)
$-0.47

Balance sheet

Total assets
$191.1M
Current assets
$106.0M
Total liabilities
$34.1M
Current liabilities
$8.0M
Shareholders’ equity
$157.0M

Cash flow

Operating cash flow
-$50.7M
Investing cash flow
$35.2M
Financing cash flow
$214.0K
Net cash flow
-$15.3M

Statements via Polygon.io (SEC filings)

NASDAQ: NAUT
$1.69 -4.52%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$0.64 $3.95

52-week range

Market cap
$214.8M
EPS (diluted)
$-0.47
Shares outstanding
179.7M
Open
Day range
Prev close
Volume
IPO date
Jun 10, 2021

Nautilus Biotechnology, Inc. (NAUT) Stock Price

  • Reported a net loss of $59.0M.
  • Trading 57% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review Nautilus Biotechnology, Inc..

Write a review
Newsroom

News about Nautilus Biotechnology, Inc.

News & sentiment via Polygon.io

FAQ

Nautilus Biotechnology, Inc.: frequently asked questions

Is Nautilus Biotechnology, Inc. an American company?

Nautilus Biotechnology, Inc. is a US-based company headquartered in Seattle, Washington, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Nautilus Biotechnology, Inc. headquartered?

Nautilus Biotechnology, Inc. is headquartered in Seattle, Washington, United States.

Is Nautilus Biotechnology, Inc. publicly traded?

Yes — Nautilus Biotechnology, Inc. is a publicly traded company. Its stock trades under the ticker symbol NAUT on the NASDAQ.

What does Nautilus Biotechnology, Inc. do?

Nautilus Biotechnology, Inc. is an American Medical Devices company in the Health & Beauty sector.

Explore

Similar companies

Browse all →